MY ACCOUNT | NEWSLETTER |

Comparison of the effects of corticosteroids on ocular parameters in horses


This research was performed to compare the effects of prednisolone and fluorometholone on intraocular pressure (IOP) and Schirmer tear test (STT) in the normal equine eye. 

Sixteen normal mares aged between 6 and 10 years were used for this study. Horses were randomly assigned to two groups. Eight horses in the first group received 0.2 mL of topical 1% prednisolone in one eye and the contralateral eye was used as control (0.2 mL of saline was instilled). The second group received 0.2 mL of 0.1% fluorometholone in a randomly selected eye and the contralateral eye served as control and received 0.2 mL of saline. STT values and IOP were determined using STT strips and rebound, respectively, at the baseline, and 30-, 60-, 90-, and 180-min post eyedrop instillation. 

Mean (SD) IOPs at the baseline in the treated eyes of the first and second groups were 28.5 (5.4) and 27.5 (4.9) mmHg, respectively. STT values at the baseline in the treated eyes of the first and second groups were 26.0 (1.8) mm/min and 24.0 (4.0) mm/min, respectively. Neither prednisolone nor fluorometholone caused significant changes in the IOP during 3 h of monitoring (P > 0.05). There were no significant differences in the mean levels of STT in the control and treatment eyes, either between groups or within each group (P > 0.05). 

In conclusion, one dose (0.2 mL) of 1% prednisolone or 0.1% fluorometholone after 3 hours did not alter the IOP and STT in healthy horses. Further studies with longer durations in normal horses and horses with uveitis are warranted.



“Comparison of the effects of 0.1% fluorometholone and 1% prednisolone on intraocular pressure and Schirmer tear test in equine eye”. Taraneh Atai, et al. J Equine Vet Sci. 2023 Jun 20;104840.  doi: 10.1016/j.jevs.2023.104840.

Source: https://www.sciencedirect.com/science/article/abs/pii/S0737080623006470


Like0
Dislike1
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

EXPRESS: Azotaemia and outcomes in male cats with initial and recurrent urethral obstruction: a multicentre retrospective study of 601 cats (2020-2024).

Like0
Dislike0

Clinical findings and risk factors for clinical outcomes in dogs with myxomatous mitral valve disease hospitalized for cardiogenic pulmonary edema.

Like0
Dislike0

Soluble triggering receptor expressed on myeloid cells-1 as a predictive biomarker in sepsis: insights into cut-offs, mortality risk, and treatment guidance-secondary analysis of the Next GeneSiS-Trial.

Like0
Dislike0

Texas A&M Research Reveals More Than 84% Of Dogs Show Signs Of Fear, Anxiety

Like0
Dislike0

Veterinary Pharmaceuticals Market Research and Global Forecast Report 2026-2031: Rising Demand for Parasiticides and Dermatology Products and Growth Potential in

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2026 - All Rights Reserved
ISSN 2768-198X

Top